Cargando…
Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2
B-cell and T-cell lymphomas and leukemias often have distinct genetic mutations that are diagnostically defining or prognostically significant. A subset of these mutations consists of specific point mutations, which can be evaluated using genetic sequencing approaches or point mutation specific anti...
Autores principales: | Singh, Kunwar, Gollapudi, Sumanth, Mittal, Sasha, Small, Corinn, Kumar, Jyoti, Ohgami, Robert S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065453/ https://www.ncbi.nlm.nih.gov/pubmed/33801781 http://dx.doi.org/10.3390/diagnostics11040600 |
Ejemplares similares
-
Case Report: Castleman Disease With an Associated Stromal Spindle Cell Proliferation, PDGFRB Mutation and p53 Expression: Clonal Origins of a Rare Disease
por: Singh, Kunwar I., et al.
Publicado: (2022) -
Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors
por: Zorzan, Eleonora, et al.
Publicado: (2015) -
IRF3 and IRF8 Regulate NF-κB Signaling by Targeting MyD88 in Teleost Fish
por: Yan, Xiaolong, et al.
Publicado: (2020) -
A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease
por: Butzmann, Alexandra, et al.
Publicado: (2021) -
Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas
por: Wróblewska, Joanna P., et al.
Publicado: (2021)